GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (OTCPK:BIOAF) » Definitions » Profitability Rank
中文

Bioasis Technologies (Bioasis Technologies) Profitability Rank

: 0 (As of Nov. 2022)
View and export this data going back to 2009. Start your Free Trial

Bioasis Technologies has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Bioasis Technologies's Operating Margin % for the quarter that ended in Nov. 2022 was -467.57%. As of today, Bioasis Technologies's Piotroski F-Score is 0.


Competitive Comparison

For the Biotechnology subindustry, Bioasis Technologies's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies Profitability Rank Distribution

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Profitability Rank falls into.



Bioasis Technologies Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Bioasis Technologies has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Bioasis Technologies's Operating Margin % for the quarter that ended in Nov. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Nov. 2022 ) / Revenue (Q: Nov. 2022 )
=-0.519 / 0.111
=-467.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Bioasis Technologies has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Bioasis Technologies Profitability Rank Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies (Bioasis Technologies) Business Description

Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (Bioasis Technologies) Headlines